Kura Oncology (NASDAQ:KURA) CEO Sells $327,338.10 in Stock

Key Points

• Kura Oncology CEO Troy Edward Wilson sold 36,615 shares at an average price of $8.94, totaling $327,338.10, which reduced his ownership stake by 12.92%.
• The company's most recent earnings report showed a loss of ($0.75) earnings per share, missing the consensus estimate of $0.15 by ($0.90).
• Kura Oncology has a market cap of $778.60 million and a consensus rating of "Moderate Buy" with a price target of $24.10.

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) CEO Troy Edward Wilson sold 36,615 shares of the firm's stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $8.94, for a total value of $327,338.10. Following the transaction, the chief executive officer owned 246,853 shares in the company, valued at $2,206,865.82. This represents a 12.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Troy Edward Wilson also recently made the following trade(s):

• On Monday, September 8th, Troy Edward Wilson bought 50,000 shares of Kura Oncology stock. The stock was bought at an average price of $8.20 per share, for a total transaction of $410,000.00.

Kura Oncology Stock Performance

Shares of KURA stock traded down $0.08 during midday trading on Monday, hitting $8.97. The company had a trading volume of 2,168,205 shares, compared to its average volume of 1,613,537. The company's 50 day simple moving average is $7.39 and its 200 day simple moving average is $6.65. Kura Oncology, Inc. has a 52-week low of $5.41 and a 52-week high of $19.93. The stock has a market cap of $778.60 million, a price-to-earnings ratio of -3.97 and a beta of 0.19. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.16 and a quick ratio of 6.16.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.90). The business had revenue of $15.29 million during the quarter, compared to the consensus estimate of $64.95 million. Research analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

KURA has been the subject of several recent research reports. Guggenheim started coverage on Kura Oncology in a research report on Thursday, September 4th. They set a "neutral" rating for the company. Wedbush reaffirmed an "outperform" rating and issued a $36.00 price objective on shares of Kura Oncology in a research report on Friday, June 20th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Kura Oncology in a research report on Thursday, June 26th. Wall Street Zen raised Kura Oncology from a "sell" rating to a "hold" rating in a research report on Sunday, August 17th. Finally, JMP Securities lowered their price objective on Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating for the company in a research report on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, Kura Oncology has a consensus rating of "Moderate Buy" and a consensus price target of $24.10.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of KURA. Ameriprise Financial Inc. acquired a new position in shares of Kura Oncology during the fourth quarter worth about $130,000. ProShare Advisors LLC lifted its stake in shares of Kura Oncology by 32.2% during the fourth quarter. ProShare Advisors LLC now owns 24,103 shares of the company's stock worth $210,000 after purchasing an additional 5,873 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of Kura Oncology during the fourth quarter worth about $799,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Kura Oncology by 7.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 131,718 shares of the company's stock worth $1,147,000 after purchasing an additional 9,050 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Kura Oncology by 5.2% during the first quarter. Rhumbline Advisers now owns 105,206 shares of the company's stock worth $694,000 after purchasing an additional 5,215 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.